UPDATE: The most recent study by Oxford University (randomized control trial) showed a 90% reduction in hospitalization for people with COVID.
Below are links to a peer-reviewed studies, articles in medical journals, or news articles regarding the efficacy of budesonide.
Medical Journal Articles or Studies
- Common asthma treatment reduces need for hospitalisation [by 90%] in COVID-19 patients, study suggests (University of Oxford)
- Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection – ScienceDirect (from the American Journal of Medicine)
- Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) (Reviews in Cardiovascular Medicine)
- Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective (from European Respiratory Journal)
- Inhaled corticosteroids in virus pandemics: a treatment for COVID-19? (From The Lancet)
- SARS-CoV-2 and The Case for Empirical Treatment (The Global Journal of Science Frontier Research – Volume 20, Issue 4)
- Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection (US National Library of Medicine National Institutes of Health)
- Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients (US National Library of Medicine National Institutes of Health)
- Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome (US National Library of Medicine National Institutes of Health)
News Reports & Studies
- Common asthma drug cuts COVID-19 hospitalization risk, recovery time – Oxford study (Reuters)
- Common asthma drug cuts need to send Covid patients to hospital by 90 per cent and shortens recovery time, Oxford University scientists say (The Daily Mail)
- Common asthma drug can reduce COVID hospitalizations by 90% — study (The Times of Israel)
- Common asthma drug slashes Covid hospitalisation by 90%, experts say (The Sun)
- Coronavirus: Inhaling this can reduce COVID severity by 90 per cent, claims study (The Times of India)
- University of Oxford Does it Again! Now Showing that AstraZeneca’s Pulmicort Reduces COVID-19 Hospitalization Rate by 90% (Trial Site news)
- Common asthma treatment reduces need for hospitalization in COVID-19 patients, study suggests (Medical Express)
- Study finds that inhaled budesonide can reduce severity of and speed recovery from COVID-19 (OINDP News)
- Innovative Budesonide Treatment Key to West Texas Woman’s Remarkable Coronavirus Recovery (The Texan)
- Some Texas Doctors Are Treating COVID Patients With A ‘Silver Bullet’ Drug (Texas Standard)
- Is a new steroid treatment a miracle solution for COVID-19—or is it snake oil? (Fortune Magazine)
Below are links to studies or articles about the efficacy or success of some of the other remedies we recommend for prevention.
- Mouthwash eliminates coronavirus in 30 seconds… in the lab (BBC Science Focus)
- Library of Articles and Studies on the success of the H2Bev drinks (H2Bev website)
- Vitamin D can help reduce coronavirus risk by 54%: Boston University doctor (Boston Herald)
***Medical disclaimer: This website was created for informational purposes only and has no ties to any drug company or physician. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. In addition, no one involved in this website has financial ties to any of the suggested therapies. We are merely patient advocates, trying to save lives and fight medical censorship.***